Melanoma Awareness and Research at Illinois CancerCare. ILCC Research is nationally recognized for it’s contribution to practice changing trials over the decades and providing tomorrow’s treatments today for Melanoma patients in central Illinois.

With summertime and sunny days here, Dr. Madhuri Bajaj and Clinical Research Coordinator Carrie Geoffroy discuss our ongoing melanoma clinical trial, where they addressed a common placebo myth, how today’s standard of care was established, and the critical role research plays in improving patient outcomes. Clinical trials are essential to driving innovation and advancing new therapies. We’re proud to have a highly collaborative team of researchers and physicians dedicated to moving oncology care forward and bringing the next generation of treatment options to patients.💡☀️🎗️ The US Oncology Network | McKesson | McKesson Oncology & Multispecialty #ClinicalResearch #Oncology #Melanoma #ClinicalTrials #HealthcareInnovation #ResearchCollaboration

#Biokinetica Case Study: Accelerating Complex Early Phase Oncology Studies 🔬 Delivering successful early phase oncology trials requires more than efficient recruitment — it demands operational precision, strong referral networks, and sustained patient engagement. In a recent oncology DDI study involving patients with multiple solid tumor types, Biokinetica supported the delivery of complex recruitment and retention pathways within a highly demanding clinical environment. This was achieved through close coordination across clinical and operational teams, streamlined start-up and screening processes, and strong collaboration with a nationwide referral network. A patient-centric approach throughout the study helped support adherence and continuity of care. 👇 The study below reflects Biokinetica’s ability to execute complex early-phase oncology programs with consistency, flexibility, and a strong focus on patient experience. Looking to accelerate your next oncology study? Get in touch to learn how Biokinetica can support your clinical development goals. #Oncology, #OncologyCaseStudy, #PatientRecruitment, #EarlyPhase, #Phase1, #ClinicalResearch, #DrugDevelopment

The Journal of Clinical Oncology just dropped Issue 18 June 20, 2026. 📖 And for anyone working in oncology clinical research, this issue deserves your full attention. Two areas stand out for me personally this week: 🔵 Renal Cell Carcinoma Dr Rana R. McKay features in this issue with data that continues to shape how we think about frontline RCC management. Having managed a Renal Cell Carcinoma PK/PDA study at Med Tricare Clinical Research, I have seen firsthand what running an RCC trial looks like from the site side the patient profile, the complex eligibility criteria, the monitoring demands. When I read RCC data in JCO, I don't just read the hazard ratios. I think about the site coordinators who screened those patients at 7am. The monitors who flew out for surveillance visits. The TMF teams ensuring every adverse event was captured in real time. The science published in JCO is only as strong as the clinical operations infrastructure behind it. 🟠 Brain Tumours Dr Patrick Y. Wen's work in this issue touches on one of the most difficult spaces in all of oncology. Brain tumours remain among the deadliest cancers resistant to almost all conventional and novel treatments. Yet the data emerging in 2026 from personalised DNA vaccines in glioblastoma to precision-guided therapy in diffuse midline gliomas signals something is shifting. For clinical operations teams working on neuro-oncology trials, these studies bring unique challenges: CNS eligibility criteria, neurological assessment scheduling, imaging protocol complexity, and patient vulnerability unlike almost any other oncology indication. Running these trials well requires more than GCP compliance. It requires genuine clinical understanding. This is what I mean when I say oncology clinical operations is a specialty in its own right — not a generic skill set applied to a therapeutic area. 🔗 Read JCO Issue 18: ascopubs.org/journal/jco ♻️ Repost if this resonates with someone in your network. 📌 Tagging: @ASCO @Journal of Clinical Oncology @NIHR @NHS England @MHRA @University of Bristol @OncoBridge Clinical #JCO #JournalOfClinicalOncology #Oncology #RenalCellCarcinoma #BrainTumour #Glioblastoma #ClinicalResearch #ClinicalTrials #ClinicalOperations #OncoBridgeClinical #SiteManagement #TMF #GCP #PharmaCareers #HealthcareLeadership #Bristol #ASCO2026 #DrugDevelopment

Read our latest quarterly Advocacy Newsletter and catch up on important developments across oncology, mark your calendar for upcoming Friends of Cancer Research meetings, and read the latest resources from our team. This issue features: ▪️ Highlights from our public meetings and webinars on External Control Arms, Next-Generation Therapies, and the Biomarker Qualification Program ▪️ An Advocate Insights blog by Advisory Advocate Misha Mehta PhD, BCPA sharing her son Neev's Diffuse Intrinsic Pontine Glioma journey and how it drives her continued advocacy for federal funding in critical areas, such as pediatric brain tumor research ▪️ Our new analysis evaluating how post-market commitments are being used to support development of companion diagnostics, particularly for ultra-rare and rare cancers ▪️ A recap of the April 30 Oncologic Drugs Advisory Committee (ODAC) meeting and our public comment on the FDA's new Plausible Mechanism Framework draft guidance Read the latest issue and subscribe to stay informed: https://lnkd.in/ecYT5mmv. #patientadvocacy #cancerresearch

IAIO Expert Insights – Gynecologic Oncology | Event Highlights The IAIO Expert Insights session on Gynecologic Oncology brought together renowned oncology experts for an engaging evening of scientific exchange and clinical learning. Under the guidance of Program Director Prof. Dr. Ghanashyam Biswas, the session featured insightful presentations and panel discussions led by distinguished faculty including Dr. Dipti Rani Samanta,Subhashree Subhasmita Dash, Dr. Sushant, Dr. Chandan Kumar Jena, Dr. Srigopal Mohanty, and Soumya Surath Panda. The event also benefited from the leadership of esteemed chairpersons Deepak Rautray , Dr. Satyanarayan Senapati MCh, and Dr. NVS Ramakrishna MD(Internal Medicine) DM(Medical Oncology), who facilitated thought-provoking discussions on evolving approaches to endometrial and ovarian cancer management. Thank you to all faculty members, delegates, and partners for making this educational initiative a success. 📌 Stay updated with the latest oncology insights, expert discussions, and educational initiatives from IAIO. Access the complete event highlights through the link below. https://lnkd.in/gMG5_J-A #IAIO #ExpertInsights #GynecologicOncology #OncologyEducation #CancerCare #MedicalEducation #IntegratedOncology #WomenCancerCare

The next bottleneck in precision oncology For much of the past two decades, the focus of precision oncology has been on developing better therapies. And rightly so. Targeted therapies, immunotherapies, ADCs, radioligand therapies, cell therapies, and RNA-based approaches have transformed what is possible for patients. But as therapies become more sophisticated, a different challenge is emerging. The question is no longer only: - "Can we develop the therapy?" Increasingly it is: - "Can we identify the patients most likely to benefit?" Many of the most important developments in oncology today are not new drugs, but advances in clinical trial methodology, translational research, response assessment, real-world evidence, patient-reported outcomes, and biomarker-driven patient selection. In other words, the bottleneck is gradually shifting from treatment development alone to evidence generation and clinical decision support. Better therapies remain essential. But better therapies are only half of precision medicine. The other half is understanding the biological states that predict therapeutic response. That challenge will only become more important as next-generation therapies continue to advance. #PrecisionMedicine #Oncology #ClinicalResearch #CompanionDiagnostics #TranslationalResearch #Biomarkers

#ASCO2026 showcased remarkable scientific advances across oncology—from breakthrough therapies in pancreatic cancer to targeted treatments moving into earlier-stage disease. But demonstrating efficacy in a clinical trial is only the beginning. As innovation accelerates, researchers, clinicians, and health systems are increasingly focused on the next set of questions: 🔹 Which patients are most likely to benefit? 🔹 How do new therapies perform in broader, more diverse populations than those enrolled in clinical trials? 🔹 Where do they fit within increasingly complex treatment sequences? 🔹 Can results observed in one setting translate across different healthcare systems and patient populations? These are the challenges that real-world evidence is uniquely positioned to help address. In our latest blog, Emily Castellanos MD, MPH, reflects on some of the most significant developments from ASCO 2026 and explores what it will take to translate promising clinical advances into meaningful impact for patients. Read more: https://lnkd.in/d4RP8p3q

BriefGlance.com called it an FDA “Dream Team” for oncology trials, and we could not agree more. With Paz Vellanki, MD, PhD, joining Harpreet Singh, MD and Nicholas Richardson, DO, MPH, Precision for Medicine now brings together three former FDA oncology leaders with deep experience across solid tumors, hematologic malignancies, biomarker strategy, novel endpoints, and complex trial design. Their collective expertise strengthens our ability to help life sciences companies navigate today’s increasingly complex oncology development landscape and advance meaningful therapies for patients who need them most. Read more about the team featured by BriefGlance: https://lnkd.in/esqxB9wd #PrecisionMedicine #Oncology #ClinicalTrials #LifeSciences

A trifecta of FDA expertise driving oncology forward. At Precision For Medicine, Paz Vellanki, MD, PhD, Harpreet Singh, MD, and Nicholas Richardson, DO, MPH bring a rare combination of FDA experience across solid tumours, haematologic malignancies, and clinical trial design. This trifecta provides a 360° perspective on regulatory expectations, biomarker strategy, and trial innovation. By uniting these complementary insights, we help our sponsors navigate complexity, anticipate challenges, and accelerate life-changing oncology therapies to patients. #PrecisionMedicine #Oncology #ClinicalTrials #RegulatoryStrategy